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Multiple sclerosis (MS) is an inflammatory autoimmune demyelinating disease affecting
the Central Nervous System (CNS), in which Th1 and Th17 cells appear to recognize
and react against certain myelin sheath components. Epidemiological evidence has
accumulated indicating steady increase in autoimmune disease incidence in developed
countries. Reduced infectious disease prevalence in particular has been proposed as
the cause. In agreement with this hypothesis, we recently demonstrated significantly
better clinical and radiological outcome in helminth-infected MS patients, compared to
uninfected ones. Parasite-driven protection was associated with regulatory T cell induction
and anti-inflammatory cytokine secretion, including increased TGF-β and IL-10 levels.
Interestingly, surface expression of TLR2, on both B cells and dendritic cells (DC) was
significantly higher in infected MS patients. Moreover, stimulation of myelin-specific T
cell lines with a TLR2 agonist induced inhibition of T cell proliferation, suppression of
IFN-γ, IL-12, and IL-17 secretion, as well as increase in IL-10 production, suggesting the
functional responses observed correlate with TLR2 expression patterns. Furthermore,
parasite antigens were able to induce TLR2 expression on both B cells and DCs. All
functional effects mediated by TLR2 were abrogated when MyD88 gene expression was
silenced; indicating helminth-mediated signaling induced changes in cytokine secretion
in a MyD88-dependent manner. In addition, helminth antigens significantly enhanced
co-stimulatory molecule expression, effects not mediated by MyD88. Parasite antigens
acting on MyD88 induced significant ERK kinase phosphorylation in DC. Addition of the
ERK inhibitor U0126 was associated with dose-dependent IL-10 inhibition and reciprocal
enhancement in IL-12, both correlating with ERK inhibition. Finally, cytokine effects and
changes observed in co-stimulatory DC molecules after helminth antigen exposure were
lost when TLR2 was silenced. Overall, the data described indicate that helminth molecules
exert potent regulatory effects on both DCs and B cells from MS patients through TLR2
regulation.
Keywords: multiple sclerosis, parasites, helminth, toll-like receptors, soluble egg antigen, MyD88, mitogen
activated protein kinase
INTRODUCTION
Multiple Sclerosis (MS) is a chronic autoimmune mediated dis-
ease of the Central Nervous System (CNS) characterized by
inflammation, demyelination, and axonal loss (McFarland and
Martin, 2007). Although its etiology remains unknown, sev-
eral lines of evidence support the notion that autoimmunity
plays a major role in disease development and susceptibility. It
is generally accepted that both MS and experimental autoim-
mune encephalomyelitis (EAE), an animal model resembling MS,
involve Th1 and Th17 cells recognizing certain myelin sheath
components (Goverman, 2009). Autoimmune diseases such as
MS are currently thought to be caused by a combination of
individual genetic susceptibility and external environmental fac-
tors (Marrie, 2004; Oksenberg and Baranzini, 2010). The genetic
component of MS is believed to result from the action of com-
mon allelic variants in several genes. However, discordance of MS
among monozygotic twins suggests that additional factors, such
as environmental modulators could be involved (Oksenberg and
Baranzini, 2010).
Several studies implicate infectious and non-infectious envi-
ronmental factors present during childhood and young adult-
hood as strong determinants of MS risk, although their exact
nature remains unidentified. Microbial infections can act as trig-
gers inducing or promoting autoimmunity, resulting in clini-
cal disease manifestations in genetically predisposed individuals.
Alternatively, infections could accelerate sub-clinical autoim-
mune processes (Christen and von Herrath, 2005; Correale et al.,
2006). In contrast to this view, epidemiological and experimental
evidence has accumulated in recent decades indicating a steady
increase in autoimmune disease incidence in developed coun-
tries, which have been associated to a decline in infectious disease
prevalence (Bach, 2002). These observations suggest infections
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may protect rather than induce or accelerate autoimmune dis-
eases like MS.
Several studies both in humans and in animal models have
shown helminths to be powerful modulators of host immune
responses (La Flamme et al., 2003; Sewell et al., 2003; Jankovic
et al., 2006). Following this premise, we recently demonstrated
that helminth-infected MS patients showed significantly lower
disease activity, compared to uninfected MS subjects (Correale
and Farez, 2007). In addition, we provided evidence that autoim-
mune response down-regulation, secondary to parasite infection
in MS patients was mediated through regulatory cell activity,
the effect of which extended well beyond classical response to
pathogens (Correale and Farez, 2007).
Dendritic cells (DCs) in parasite infected hosts express a
range of pattern recognition receptors (PPRs), including Toll-like
receptors (TLRs), nucleotide-binding oligomerization domain-
like receptors (NLRs), retinoic acid-inducible gene-like recep-
tors (RIG-like receptors), and C-type lectin receptors (CLRs).
Upon engagement, signaling cascades are triggered inducing gene
expression involved in DCmaturation, and in priming and skew-
ing regulatory T cell immune responses (Kane et al., 2004). The
fact that helminths can both activate and negatively regulate TLR
expression indicates just how a tight control over the immune
response these infections exert.
BASIC IMMUNOLOGY OF MS
Plaques of inflammatory demyelinitation within the CNS are the
pathologic hallmarks of MS. Typical features of the acute plaque
include ill-definedmargins of myelin loss, infiltration by immune
cells, and parenchymal edema (Frohman et al., 2006). The con-
stituents of immune cell influx around vessels include T cells,
B cells, monocytes, and macrophages. The presence of lympho-
cytes within plaques and bordering areas suggests inflammatory
destruction observed in MS is driven by antigen-specific cells
targeting myelin and other CNS components. The determina-
tion that EAE can be mediated by CD4+ T cells has promoted
intense investigation into potential CD4 T-cell targets in MS.
However, how these T cells become abnormally activated against
CNS antigens remains unclear. New research has focused on the
different roles of CD4+ T cell subsets in MS. Following activa-
tion, naïve T cells differentiate into various T cell populations
with different effector functions (Boppana et al., 2011). Th1
cells produce pro-inflammatory cytokines such as IFN-γ activat-
ing macrophages. Th2 cells secrete anti-inflammatory cytokines
such as IL-4. Dysregulation of the balance between Th1 and Th2
cytokines has long been implicated in MS immunopathogene-
sis. Th17 represents a distinct lineage of effector T cells. IL-23
produced by macrophages and DCs is critical for expansion of
Th17 cells synthesizing pro-inflammatory cytokines such as IL-
17A and IL-17F (Korn et al., 2009). Interestingly, Th17 to Th1
ratio appears to be a critical determinant of CNS inflammation,
with high Th17 to Th1 ratios linked to T cell infiltration and
CNS inflammation (Strommes et al., 2008). Cytotoxic CD8+
T cells which are present in MS lesions in significant numbers
may also contribute to tissue damage by attacking oligodendro-
cytes and transecting axons (Babbe et al., 2000; Neumann et al.,
2002).
Natural occurring regulatory T cells (CD4+CD25+ FoxP3+;
Treg) comprise a small number of CD4+ T cells that have been
implicated in MS pathogenesis. Although Treg cell numbers in
peripheral blood and CSF appear to be similar in MS patients
and in healthy controls, several studies point to defects in the
capacity of Tregs from MS patients to suppress myelin-specific
T cell activation in the periphery (Viglietta et al., 2004). In addi-
tion to CD4+CD25+FoxP3+ Treg, in vitro antigen activation
leads to Foxp3 expression in CD8+ T cells. This enables CD8+
T cells to also acquire suppressive activity (Correale and Villa,
2010).
Although an autoreactive T cell-mediated immune response
has been considered critical for MS pathogenesis, increasing evi-
dence indicates that B cells also play a key role, as indicated by the
presence of B cells, plasma cells, immunoglobulins, and comple-
ment deposition in autopsy tissues from MS patients, along with
immunoglobulin-myelin complex within macrophages (Genain
et al., 1999). Intrathecal IgG synthesis, and the recent finding of
B-cell lymphoid follicles in the meninges of MS patients with pro-
gressive disease, further support this concept (Magliozzi et al.,
2007; Franchiotta et al., 2008). In addition, B cells may promote
neuroinflammation in MS via secretion of pro-inflammatory
cytokines such as TNF-α, and lymphotoxins in the presence of
T cell-derived cytokine IFN-γ (Bar-Or et al., 2010). Conversely,
B cells are also likely to have immune-suppressive properties.
For example, IL-10 secretion by B cells can serve to limit pro-
inflammatory autoreactive CD4+T cell response (Fillatreau et al.,
2002).
Immune access to the CNS is generally considered to be
restricted. Only by engaging in a critically timed sequence of
events can autoreactive lymphocytes enter the CNS compart-
ment. Initially, leukocyte engages in rolling, activation, and arrest
along the Blood-Brain Barrier endothelium. This initial step
is greatly facilitated by upregulation of endothelial cell adhe-
sion molecules, including ICAM-1 and VCAM-1 (Piccio et al.,
2002). Changes in the vascular endothelium could result from
pro-inflammatory mediators circulating within the vasculature,
including TNF-α, and IFN-γ. The complex sets of molecules that
leukocytes depend on for entry into the CNS are integrins, a
group of molecules mediating adhesion between cells. Among a
panel of leukocyte adhesion receptors, VLA-4 was identified as the
crucial factor for encephalitogenic T-cell binding to the endothe-
lium (Yednock et al., 1992). In addition, leukocyte migration to
the CNS is increased through the action of chemokines and their
receptors, which have been implicated in leukocyte influx into the
CNS observed in MS (Holman et al., 2011).
Antigen presenting cells (APCs) also play an important role in
the initiation and progression of MS. DCs are a group of APCs
which modulate adaptive immune responses, usually present in
perivascular spaces, the choroid plexus, and the meninges of
healthy brains (Serafini et al., 2006). In MS, DCs among other
cell types are recruited to the CNS, representing the major APCs
during the secondary phase of cognate interactions with CD4+
T cells within the CNS (Greter et al., 2005). In addition to
DCs, microglia, as resident APCs localized in active plaques,
play an important role in antigen presentation. Upon activation,
microglial cells express greater amounts of Class II MHC and
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co-stimulatory molecules, promoting pro-inflammatory T cell
responses within the CNS (Lassmann et al., 2001).
Although MS was classically described as a disease marked
by the loss of myelin, axonal loss has also been observed even
in the earliest pathology reports on the disease (Charcot, 1868).
Mechanisms for axonal damage are manifold and include: a
specific immunological attack on axons (Medana et al., 2001;
Neumann et al., 2002); the presence of soluble mediators such
as proteases and free radicals released as part of the inflamma-
tory environment present in the CNS of MS patients (Smith
and Lassmann, 2002), or lack of neurotrophic factors provided
to the axon by oligodendrocytes as a result of demyelination
(Frohman et al., 2005). As a consequence of immune-mediated
injury to myelin, higher energy demands on demyelinated
axons and glutamate-mediated excitotoxicity may impart fur-
ther unsustainable damage (Werner et al., 2001; Mahad et al.,
2009).
Figure 1 summarizes the most important mechanisms
involved in MS pathogenesis.
THE EAE MODEL
Dissecting the pathogenesis of a disease as complex as MS in
humans is fraught with many problems, particularly those asso-
ciated with clinical and genetic heterogeneity. Because brain and
spinal cord tissue cannot easily be sampled inMS patients in vivo,
a number of animal models have been generated to provide
insights into the underlying pathology, as well as to identify
surrogate biomarkers and therapeutic targets. The basic proto-
col for inducing EAE involves immunizing animal strains/species
using either foreign or self proteins from the white matter of
the nervous system, usually myelin basic protein (MBP), pro-
teolipid protein (PLP), or myelin oligodendroglial glycoprotein
(MOG; Steinman, 1999). Immunization leads to the develop-
ment of a disease state in the animals which shows physical
and neuropathological similarities to human MS. Clinical course
varies from acute monophasic episodes of paralysis in some, to
chronic-relapsing neurological episodes and progressive disabil-
ity in others (Furlan et al., 2009). The episodes correlate with
the perivascular mononuclear cell infiltrates in the CNS and in
FIGURE 1 | Mechanisms involved in MS pathogenesis. (1) Peripheral activation; (2) Migration of activated lymphocytes across the Blood-Brain-Barrier;
(3) Reactivation of lymphocytes in the CNS and secretion of pro-inflammatory mediators; (4) Induction of demyelination; (5) Induction of axonal damage.
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some species and strains extensive myelin destruction and axonal
loss (Mix et al., 2010). After an initial period of experimentation
with active sensitization, murine models of chronic demyelina-
tion progressed to adoptive-transfer technologies, whereby CNS
antigen-specific bulk-isolated lymphocytes, T cell lines or T
cell clones were administered intravenously into naïve recipients
(Brown and McFarlin, 1981). Recently, transgenic murine mod-
els have been developed in which disease arises spontaneously,
mostly through insertion of myelin-specific human T cell recep-
tors and human histocompatibility complex antigens (Ellmerich
et al., 2005; Pöllinger et al., 2009).
Although many features of EAE reflect what is known about
the pathophysiology of MS, discrepancies between EAE and MS
remain. Extrapolations must therefore be made with caution
when predicting what might happen in MS, based on results
obtained in EAE (Baker et al., 2011). One critical limitation
is that most EAE studies use injection with antigenic material
to induce disease onset. This clearly contrasts with the sponta-
neously arising nature of MS. Transgenic murine models offer a
possibility to overcome this limitation. However, these are highly
manipulated mice and the exact antigen(s) involved in MS is
not yet known, generating limitations in the use of models.
Another potential limitation is that EAE research is mostly con-
ducted on highly inbred animals (Handel et al., 2011). Finally, the
degree of clinical disease in the EAE model is typically reflected
by the lesion load within the spinal cord (Allen et al., 1993).
Although some animal strain/species may particularly develop
cerebellar lesions, the brain in many EAE models is relatively
unaffected (Betelli, 2007). Problematic aspects of animal mod-
els are in no way confined to MS alone, and limitations in
models should be acknowledged when placing research findings
into perspective. Clearly, studies on EAE, despite relative ease,
are no substitute for research on bona fide specimens from MS
patients.
HELMINTH INFECTIONS MODULATE IMMUNE
RESPONSE AND ALTER CLINICAL COURSE OF MS
The best evidence on parasite infections causing immune
response modulation in autoimmune diseases derives from
animal models. Pre-established infection with the helminth
Schistosoma mansoni, or pre-treatment of mice with S. man-
soni ova significantly attenuates clinical course, reduces inci-
dence and delays onset of EAE in mice, and is associated with
decreased IFN-γ, TNF-α, IL-12 and nitric oxide production by
splenocytes, as well as increased production of IL-10 and TGF-β
(La Flamme et al., 2003; Sewell et al., 2003). Moreover, IL-
12p40 transcript levels are dramatically reduced in the spinal
cord of S. mansoni infected animals, correlating with decreased
macrophage-infiltrates in brain and spinal cord. Although CD4+
T cell levels are similar during the disease peak, they fall signif-
icantly 6 week post-stimulation, suggesting schistosomiasis may
affect EAE course by targeting the macrophage compartment, and
down-regulating effector functions mediated by T cells. Likewise,
infection with Fasciola hepatica also exerts bystander suppression
of immune responses to autoantigens and attenuates clinical signs
of EAE (Walsh et al., 2009). Protection is associated with autoanti-
gen IFN-γ and IL-17 production suppression. Th1 and Th17
response is maintained in IL10−/− mice, but abrogated by in vivo
TGF-β neutralization, indicating that F. hepatica induced TGF-
β plays a critical role in the suppression of auto-antigen specific
Th1 and Th17 responses. Similarly, in mice infected with Taenia
crassiceps symptom severity was significantly reduced in 50% of
the animals, an effect associated with decreased MOG-specific
splenocyte proliferation and IL-17 as well as TNF-α production.
Moreover, parasite infection induces an increased production of
IL-4 and IL-10, as well as limited leukocyte infiltration in the
spinal cord and brain (Reyes et al., 2011). Therefore, the molecu-
lar mechanisms responsible for these beneficial effects on disease
course seem to differ depending on the helminth species, or
helminth-derived products used, and in addition may be host and
disease dependent as well.
Recent epidemiological studies demonstrated a dichotomous
relationship between worldwide distribution of MS and the par-
asite Trichuris trichiura, a common human pathogen. MS preva-
lence appears to fall steeply once a critical threshold ofT. Trichiura
(about 10%) is exceeded (Fleming and Cook, 2006). Longitudinal
studies including those tracking the prevalence of MS in response
to changing sanitation and levels of infection would be very infor-
mative to understand the role of helminths in the modulation of
MS. In this regard, the increase in MS prevalence in the French
West Indies between 1978 and 1994 was correlated with a signif-
icant reduction in intestinal parasitism during the same period
(Cabre et al., 2005). Although intriguing and provocative the
data only demonstrate association, but in no way prove causality.
Sanitation may simply be a marker for more fundamental social
or environmental factors in developed countries that are directly
linked to MS etiology (Fleming and Cook, 2006).
Recently, we identified a group of 12MS patients (8 women,
4 men; mean age 34 ± 6.8 years) presenting eosinophilia subse-
quently determined to be caused bymild, asymptomatic intestinal
parasitosis, a diagnosis confirmed in all patients by positive stool
examination (Correale and Farez, 2007). Three patients were
infected with Hymenolepis nana, three with Trichuris trichiura,
three with Ascacris lumbricoides, two with Strongyloides sterco-
laris, and one with Enterobius vermicularis. At time of eosinophil
count, helminth egg load values ranged between 1180 and 9340
eggs/gr of stool. Presence of other endemic parasitoses, including
trypanosomiasis, leishmaniasis, amebiasis, giardasis, and toxo-
plasmosis, were ruled out in this population both by micro-
scopic stool examination and serological testing. Investigations
were always negative, excluding simultaneous presence of these
infections. Patients were matched and compared to 12 unin-
fected MS subjects. Following standard medical practice as well
as tropical medicine expert recommendations indicating asymp-
tomatic adult patients usually do not require treatment, parasite
infected MS patients were not given anti-helminth medication.
Both groups were followed for approximately 4.5 years during
which time clinical, radiological, and immunological parameters
were compared. Parasite-infected MS patients showed signifi-
cantly lower exacerbation rate, minimal changes in disability, and
significantly lower radiological activity compared to uninfected
MS individuals.
Parasite-driven protection was associated with induction of
regulatory T cells, secreting suppressive cytokines such as IL-10
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and TGF-β, as well as CD4+CD25+FoxP3+ T cells displaying
significant suppressive function.
These findings provide evidence to support autoimmune
down-regulation secondary to parasite infections in MS patients
through regulatory T cell action, with effects extending beyond
response to the infectious agent. Evidence of regulatory T cell
presence during parasite infections is now emerging, offering a
potential explanation for mechanisms through which infected
hosts exhibit altered immune responses to bystander antigens.
In addition to the development of regulatory T cells, helminths
also induce regulatory B cells capable of dampening the immune
response through production of IL-10 in MS patients (Correale
et al., 2008). The cytokine is essential for regulatory function
development in this subset of B cells, and B cells isolated from IL-
10 knock-out mice fail to show the protective function (Fillatreau
et al., 2002). In agreement with our findings, recent observations
indicate that B cells fromMS patients exhibit relative deficiency in
their IL-10 producing capacity (Duddy et al., 2007). Interestingly,
production of IL-10 by B cells is restricted to helminth-infected
individuals exclusively. B cells from patients with infections from
other parasites such as Trypanosoma cruzi exhibit IL-10 levels
similar to those in uninfected MS patients, indicating that intra-
cellular parasites are unable to down-modulate harmful autoim-
mune responses in the way helminths do. Likewise, B cells from
paracoccidioides brasiliensis-infected patients, although expressing
Th2 immune responses after antigen-stimulation of peripheral
blood mononuclear cells (PBMC), exhibited B-cell IL-10 produc-
tion levels similar to those observed in uninfected MS patients,
suggesting that increased production of IL-10 by B cells found
in helminth-infected MS patients is not determined by the Th2
profile present in these individuals. IL-10 producing B cells iso-
lated from helminth-infected MS patients express MHC Class Ib
molecule CD1d, which is involved in antigen presentation and
in immunoregulation. Glycolipids presented by CD1d expressing
the invariant Vα14 (in mice), or Vα24 (in humans) T cell recep-
tor, activate natural killer T cells, a mechanism found to prevent
autoimmune responses in different animal models (Godfrey and
Kroneneberg, 2004). Moreover, the cytoplasmic tail of CD1d is
linked to signaling cascades associated to IL-10 transcription, sug-
gesting yet another immune regulatory mechanism (Colgan et al.,
1999).
Although these results provide clear evidence that persistent
helminth infections can induce an anti-inflammatory regulatory
network, consequently altering the course of MS, intervention
studies are necessary to establish whether a direct link between
parasites and the autoimmune response observed in MS exists.
Our initial observation on helminth-infected MS patients was
extended, and subjects prospectively studied for approximately
7.5 years. After 5.25 years, four patients required anti-helminth
treatment. Following drug administration, clinical and radio-
logical activity increased to levels observed in uninfected MS
patients (Correale and Farez, 2011). Mechanistic studies revealed
that cytokine secretion pattern reverted, with increase in IFN-γ
and IL-12 secreting cell numbers, and a robust decline in IL-10
and TGF-β secreting cells as well as in CD4+CD25+Foxp3+ T
regulatory cells. These observations provide clear evidence that
chronic helminth infections induce anti-inflammatory networks,
dampening inflammatory reactions occurring in autoimmune
diseases. Based on the observation that increased production
of IL-10 by CD4+ T cells and B cells after helminth infection
induced modulation of EAE and MS, it seems reasonable to
postulate recombinant IL-10 use (rIL-10) for MS patient treat-
ment. Increased IL-10 expression in CNS during recovery from
EAE-induced brain inflammation, suggests IL-10 presence is,
however, required within the target organ for disease remission
to occur (Kennedy et al., 1992). Because of their short half-
life, cytokines need to be administered frequently and in large
doses to provide therapeutic concentrations at the target organ
level, and systemic administration of rIL-10 for treatment of
EAE has yielded contradictory results. Intravenous injection of
rIL-10 has exacerbated, rather than suppressed EAE (Cannella
et al., 1996). In contrast, other studies have shown that peripheral
IL-10 treatment can prevent EAE, when administered systemi-
cally during the priming phase of the disease (Rott et al., 1994).
Should rIL-10 be of therapeutic benefit, then it would need to
be administered once the autoagressive response has been gen-
erated. IL-10 also, significantly inhibited the effector phase of
EAE when administered locally in the CNS using a retrovirus
vector (Croxford et al., 2001), providing an optional manner to
maintain effective levels of IL-10 when frequent injection is not
feasible. These results suggest that although rIL-10 has the poten-
tial to prevent CNS inflammation, distribution, and timing of its
production may explain its variable effectiveness (O’Garra et al.,
2008). Overall it is possible to conclude that systemic adminis-
tration of rIL-10 may yield suboptimal efficacy, while targeted
and persistent delivery of this cytokine in the CNS may be highly
effective.
EXPRESSION OF TLR IN MS PATIENTS
TLRs are type I transmembrane glycoproteins composed of extra-
cellular and intracellular signaling domains (Gay and Gangloff,
2007). They are expressed in different combinations onmany cells
of the immune system, at the cell surface and along endosomal
membranes. Extracellular TLR domains have reiterated leucine-
rich modules bearing pathogen-associated molecular patterns
(PAMPs) able to recognize a wide range of microbial products,
thus providing a link between innate and adaptive immunity
(Akira, 2003; Kawai and Akira, 2005). The microbial products
constituting PAMPs that bind to TLR can be lipids, lipopeptides,
proteins, or nucleic acids. Initially, these exogenous PAMPs were
described in the context of infection, but endogenous ligands such
as self-molecules from apoptotic cells can also trigger inflamma-
tion. In particular endogenous heat-shock proteins, extra-cellular
matrix fragments, fibrinogen, and self RNA and DNA can bind
to TLRs (Yu et al., 2010). Endogenous RNA and DNA are able
to activate TLR7 and TLR9 if they enter endosomal compart-
ment, inducing production of pro-inflammatory cytokines by
plasmocytoid DCs (Chi and Flavell, 2008). In mammals, specific
combinations of TLRs are expressed on immune cells such as
DCs,macrophages, mast cells, and to a lesser degree in fibroblasts,
epithelial cells, endothelial cells, and also in T and B cells.
The innate immune system plays an important role both
in the initiation and progression of MS influencing the effec-
tor function of T and B cells (McFarland and Martin, 2007;
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Boppana et al., 2011). In particular, recent studies have shown
that TLRs modulate MS as well as EAE (Monney et al., 2002;
Weiner, 2004; Racke and Drew, 2009), and several endoge-
nous TLR ligands have been recently identified in the MS
lesions (Lassmann, 2008). The need for the use of Complete
Freund’s adjuvant (CFA) containing mycobacteria to induce
EAE suggests TLR signaling may be important for the induc-
tion of encephalitogenic Th17 cell responses and EAE. TLR4
recognizes LPS subsequently inducing a pro-inflammatory Th1
response (Marta et al., 2009). Unexpectedly, lack of TLR4 exac-
erbates Myelin Oligodendrocyte Glycoprotein (MOG)-induced
EAE (Marta et al., 2008). TLR4−/− mice exhibited marked
increase in IL-6 and IL-23 expression by splenic myeloid DCs,
increased frequency of splenic Th17 cells, and increased levels
of serum IL-17. In contrast, MOG-specific Th1 responses are
impaired in TLR4−/− mice. This could explain the aggravated
Th17 cell response in TLR4−/−, because Th1 cells and IFN-γ
inhibit Th17 cell differentiation in vitro (Harrington et al., 2005).
Mycobacteria are rich in unmethylated CpGDNA that binds to
TLR9. The role of TLR9 in EAE has therefore been investigated.
Initial experiments demonstrated that TLR9−/− mice exhibited
ameliorated symptoms of MOG35–55 induced EAE (Prinz et al.,
2006). In contrast, other authors demonstrated that TLR9−/−
mice exhibited exacerbated symptoms of MOG-induced EAE
(Marta et al., 2009). Pro-inflammatory cytokine expression by
splenic myeloid DC and T cells is similar in TLR9−/− and wild-
type mice, suggesting cells other than myeloid DCs or T cells
are responsible for these findings (Marta et al., 2009). Several
putative explanations for exist for these conflicting results: first,
a net anti-inflammatory effect of TLR9 signaling, despite its role
in pathogenic antibody production. Second, induction of cross-
tolerance upon repeated stimulation of one TLR family. Finally,
induction of tolerance mediated by TLR9 (Marta et al., 2009).
TLR regulation may be altered by helminth parasites, affect-
ing its function and levels of expression. Our group has provided
evidence suggesting that surface expression of TLR2 on both B
cells and DCs is significantly higher in helminth-infected MS
patients (Figure 2) and that exposure of either cell population
to soluble egg antigen (SEA) obtained from S. mansoni resulted
in significant upregulation of TLR2 in helminth-infected MS
patients, but not in uninfected individuals (Figure 3; Correale
and Farez, 2009). It is well known that a variety of pathogens
can cause increased TLR expression. Some authors have found
results similar to our observations, indicating higher expression
of TLR2 on PBMCs, and enhanced response to the Pam3Cys lig-
and in Plasmodium falciparum-infected children, compared to
uninfected counterparts (Hartgers et al., 2008). Other reports,
however, show down-regulation of TLR expression to be an
important immune evasion strategy induced by some proto-
zoan parasites, and also by filarial parasites (Babu et al., 2005).
Interestingly, cells from uninfected subjects did not exhibit alter-
ations in TLR expression. It is feasible that TLRs become desen-
sitized in uninfected individuals and, consequently, SEA is not
effective in inducing changes in expression levels. Supporting this
notion, one study has shown that gut TLRs are constitutively non-
responsive to the TLR4 ligand LPS (Lotz et al., 2006). Factors
such as total body parasite burden and infection duration may
A
B
FIGURE 2 | Baseline expression of TLRs on B cells (A) and dendritic
cells (B). CD19+ B cells and dendritic cells, were isolated from peripheral
blood mononuclear cells using specific isolation kits according
manufacturer’s instructions to a purity of 95–98%. TLR2, TLR4, TLR5, and
TLR9 expression was assessed in B cells and monocyte derived dendritic
cells from helminth-infected MS patients, uninfected MS patients, and
healthy controls, using flow cytometry. Mean fluorescence intensity (MFI)
of TLR expression was corrected after subtracting MFI of the control
antibody isotype. TLR2 expression in infected MS patients was found to be
significantly higher (p < 0.001) than in uninfected MS patients or healthy
controls. In contrast, MFI of TLR4, TLR5, and TLR9 did not differ between
groups. Data represent mean values ± SEM from 12 subjects for each
group.
also play an important role in determining TLR expression lev-
els. Alternatively, differences in polymorphisms within TLR genes
or in signaling protein pathways may alter responses to differ-
ent infectious agent stimuli (Lorenz et al., 2000). Finally, lack of
SEA effect on uninfected cells may be related to engagement of a
second receptor, absent in uninfected cells.
TLR are expressed on CNS cells and can also influence local
immune responses. There is marked increase in TLR expres-
sion both in MS and EAE brain lesions, and cerebro-spinal fluid
mononuclear cells (Bsibsi et al., 2002). Both murine and human
microglia mount specific activation programs suited to differ-
ent TLR signals, particularly TLR9, linking innate and adaptive
immune responses at sites where CD4+ T cells undergo acti-
vation or proliferate (Chearwae and Bright, 2008; Marta et al.,
2009). Conversely, it was recently shown that TLR3 triggers neu-
roprotective responses in astrocytes, controlling the growth of
axons and neuronal progenitor cells (Bsibsi et al., 2010). Overall,
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FIGURE 3 | SEAupregulatedTLR2expressiononBcellsanddendritic cells,
from helminth-infectedMSpatients.B cells and dendritic cells were cultured
for 48h in the presence and in the absence of SEA, or PPD used as control
antigen. TLR expressionwas evaluated using flow cytometry, and results
expressed as mean fluorescence intensity. Following exposure to SEA, TLR2
wasmarkedly up-regulated in B cells and dendritic cells from helminth-infected
MS patients. In contrast, no significant changeswere observed in TLR2
expression after PPD exposure. Likewise, exposure to SEA did not affect TLR4,
TLR5, or TLR9 expressionon B cells or dendritic cells. Data illustrateMFI from a
representative patient. Similar results were observed in 11 additional patients.
it is clear that TLR are potent modulators of microglia cells and
macrophage activation programs in the CNS, as well as of neu-
roprotective responses. Table 1 summarizes the main biological
effects of TLRs on the course of EAE and MS.
In addition to TLRs, DCs express a variety of receptors spe-
cialized in the recognition of glycans, of which CLRs are the
most important (Weis et al., 1998). Recent data suggests glycan-
induced CLR signaling modulates inflammatory responses by
enhancing or suppressing TLR-mediated responses. DC-SIGN
especially shows interesting properties associated with Th2 polar-
ization, suppression of inflammation, and induction of regula-
tory T cell populations (Bergman et al., 2004). Mannosylated
Mycobacterial cell wall components suppressed LPS-induced
TLR4 signaling, indicating crosstalk between DC-SIGN andTLR4
(Geijtenbeek et al., 2003). In addition, one particular DC-SIGN
has been shown to be specific for the Lewisx determinant present
in S. mansoni, and may participate in the effects it has shown
on the immune response (Kuijk and van Die, 2010). Recently,
another C-type lectin, DCIR was described as suppressing TLR
activation, by inhibiting TLR-8 mediated IL-12 and TNF-α pro-
duction by DCs (Meyer-Wentrup et al., 2009). Physical interac-
tion between CLRs and other receptors at the cell surface may lead
to receptor cross-linking and further modification of intracellular
signaling (Kuijk and van Die, 2010). These observations sug-
gest helminth glycans may target C-type lectins on DCs, further
modulating their immunological functions.
MOLECULAR MECHANISMS INVOLVED IN TLR
BINDING AND SIGNALING PATHWAYS
TLR signaling has been extensively investigated in the last several
years. The cytoplasmic domain of TLR, termed Toll/interleukin-
1 receptor (TIR), is highly conserved and functions as binding
site for downstream adaptor molecules. Signaling TLR involves
a variety of adaptor proteins (Watters et al., 2007), the most
common being the myeloid differentiation marker 88 (MyD88)
signaling through all TLRs, except TLR3 (O’Neill and Bowie,
2007). Activated TLR recruit MyD88, leading to subsequent acti-
vation of downstream targets, including nuclear factor kappa
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Table 1 | Biological effects of TLR on EAE and MS.
TLR/ligand Target cell Biological effects EAE MS
TLR2/SEA B cells and DCs Upregulation of TLR2; induction of tolerogenic DCs
Increased production of eotaxin, IL-5, and IL-13, TGF-β,
and IL-10
Suppression of IL-12, IL-6, IL1-β, and TNF-α
Down regulation of LPS-induced co-stimulatory
molecules on DCs
Induction of IL-10 producing Treg cells
+ +
TLR2 and TLR4/HMGB1 Macrophages and microglia Increased expression of IL-23 +
TLR2/zymosan DCs Induction of tolerogenic DCs, increased production of
IL-10 and TGF-β
Decreased production of IL-6 and IL-12 +
TLR3 Astrocytes Triggers neuroprotective responses, controlling the
growth of axons, and neuronal progenitor cells
+ +
TLR3 Microglia Th1 cell polarization, increased production of IFN-γ
concomitant with increased CD4+ T cell death
+
TLR4/LPS T cells Induction of pro-inflammatory Th1 responses +
Myeloid DCs TLR4–/– mice shown exacerbation of MOG-induced
EAE
Increased production of IL-6 and IL-23 by myeloid DCs




TLR9/CpG DNA Myeloid DCs TLR9–/– mice exhibited ameliorated symptoms of EAE +
Other cells different from DCs
and T cells
TLR9–/– mice exhibited exacerbated symptoms of
EAE
+
TLR9 Microglia CD4+ T cells undergo activation and proliferation + +
DCs, Dendritic cells; HMGB1, High mobility group box chromosomal protein; SEA, Soluble egg antigen.
B (NF-κB), mitogen activated protein kinases (MAPKs) (p38,
JNK, and ERK1/2), KB kinase inhibitor (IKK), and interferon
regulatory factors (IRF; West et al., 2006). After endocytosis
into endosomes, both TLR3 and TLR4 signal through the TIR-
domain-containing adapter, inducing IFN-β (TRIF) to activate
downstream signaling. In addition, MyD88 adaptor-like (Mal,
also called TIRAP) is recruited by TLR2 and TLR4, and so far,
its function appears to be to subsequently stabilize MyD88 in the
complex acting as a bridge (O’Neill, 2008; Beutler, 2009).
TLR2 has been implicated as a potential receptor for SEA
immunomodulatory activities (Table 1), after observing that
schistosome-derived lipids elicited tolerogenic DCs, triggered
eotaxin, IL-5, and IL-13 production, and induced IL-10 produc-
ing regulatory T cells via TLR2 recognition (van der Kleij et al.,
2002; Magalhaes et al., 2010). Moreover, during experimentally-
induced infections, TLR2 absence was associated with enhanced
Th1 and reduced Th2 responses, and increasing disease severity
(Layland et al., 2007). It is generally accepted that schistosoma-
derived lipids signal via TLR2, whereas dsRNA from schistosomal
eggs activates TLR3 (Aksoy et al., 2005).
We have shown that SEA and TLR2 agonistsmodulate intracel-
lular pathways resulting in suppression of IL-12, IL-6, IL-1β, and
TNF-α DC production, and activation of TGF-β, as well as IL-10
production by both DCs and B cells through aMyD88-dependent
pathway (Correale and Farez, 2009). We also found SEA down-
regulated expression of LPS-induced co-stimulatory molecules
on DCs in a MyD88-independent manner (Correale and Farez,
2009). These patterns of DC response are similar to those
observed after stimulation using Giardia extracts (Kamda and
Singer, 2009). Collectively, these observations suggest SEA is able
to regulate multiple pathways downstream of TLRs, and that
schistosoma contribute to maintain an anti-inflammatory milieu
through multiple mechanisms. Supporting these findings, pre-
vious studies have demonstrated that mice with B-cell specific
deletions of TLR2 and TLR4 or of the TLR adaptor MyD88,
do not recover from EAE, indicating TLR participate directly in
regulatory functions exerted by B cells (Lampropoulou et al.,
2008). Likewise, ES-62 a glycoprotein from the rodent nema-
tode Acanthonema vitae inhibited both B and T cell activation
through the MyD88-dependent TLR4 pathway (Goodridge et al.,
2005). However, and in contrast to these observations, stud-
ies using DCs derived from TLR2−/− and TLR4−/− mice have
demonstrated that TLR2 and TLR4 are not required for SEA-
pulsed DCs to induce anti-inflammatory responses in naïve mice,
suggesting other receptors, such as C-type lectins, may be impli-
cated in DCs response capacity to SEA. Discrepancies between
investigations may be due to the presence of different moieties
in SEA preparations or, alternatively, differences in parasite Ag
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recognition between human and mouse TLR2s (Kane et al.,
2008). Figure 4 summarizes potential mechanisms for immune
regulation mediated by helminths as discussed above.
One of the major signaling cascades triggered as a result of
TLRs engagement is the MAPK pathway. Differential activation
of MAPK p38 and extracellular-signal-regulated kinase (ERK) in
DCs has been associated with varying levels of cell maturation
and cytokine production. p38 is thought to be important in DC-
maturation, and pro-inflammatory T cell responses, whereas ERK
activation hasmore often been associated with anti-inflammatory
and Th2 responses (Agrawal et al., 2003; Correale and Farez,
2009). Recent analysis of signaling pathways induced in DCs by
carbohydrates from Schistosoma eggs has indicated that TLR2
agonists induce increased phosphorylation of the MAPK ERK1/2.
Neither stimulus showed effect on p38 or JNK1/2 phosphory-
lation, however. Interestingly, ERK 1/2 activity blockade using
the specific inhibitor U0126, significantly enhanced IL-12 and
inhibited IL-10 production induced by TLR2 agonists (Agrawal
et al., 2003; Correale and Farez, 2009). In contrast, TLR4 and
TLR5 agonists have been shown to preferentially induce IFN-γ
and IL-12 via a mechanism involving p38 and JNK1/2 (Rincon
et al., 1998; Agrawal et al., 2003; Marthur et al., 2004). ERK
1/2 signaling induced by TLR2 agonists and SEA results in c-
Fos phosphorylation (Agrawal et al., 2003). Silencing of c-Fos
causes marked IL-12 production, behaving like a Th1 stimulus,
indicating that the bias toward IL-10 production observed after
TLR2 or SEA stimulation is mediated by c-Fos phosphorylation
(Agrawal et al., 2003). It is unclear at present whether SEA stim-
ulation affects other signaling cascades, such as PI3K/Akt path-
way. Identification and characterization of signaling molecules
involved in MyD88-indpendent pathways remain a challenge for
the future.
Overall, these findings provide evidence that helminth par-
asites and their antigens modulate TLR expression and conse-
quently the innate immune response, preventing host tissue dam-
age. TLR expression and function can, however, have bystander
effects such that responses to non-helminth pathogens are also
dampened inducing a protective effect against autoimmune dis-
eases such as MS. These protective effects are mediated mainly
by suppression of pro-inflammatory cytokines and activation of
IL-10, as well as by expansion of CD4+CD25+ FoxP3+ Treg
cells. Furthermore, these mechanisms are dependent on ERK 1/2
A B
C
FIGURE 4 | Summary of putativemechanisms throughwhich helminths
couldmodulateMS. (A)Helminth-derivedproducts influencethedevelopment
of specific immunosuppressivemechanisms through interactionswithdendritic
cells, and B cells. (B) Signaling-dependentmechanisms generatedby helminth
products. Binding of carbohydrates or glycolipid helminth-derivedproducts
triggerMAPKcascades, resulting inc-Fosphosphorylation. (C)Helminth-derived
products favor Th2 responses in dendritic cells by signaling-independent
pathwaysmediated by RNAses, cystatins, and cathepsins.
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signaling resulting in the phosphorylation of the early transcrip-
tion factor c-Fos.
PARASITE ANTIGENS MAY MODULATE DCs THROUGH
PPRs-SIGNALING INDEPENDENT MECHANISMS
Evidence is emerging that helminth manipulation of DCs may
also be mediated by mechanisms other than receptor-mediated
signaling events, for example, by the enzymatic activities of
helminth-derived products (Figure 4). Helminth parasites are
known to release a wide variety of enzymatically active prod-
ucts that are thought to play an important role in establishing
and maintaining infection, by contributing to the degradation
of soluble antiparasitic molecules or through impairment of
innate immune cells (Everts et al., 2010). Omega-1 a glycopro-
tein derived from schistosoma eggs specifically primes DCs to
drive polarized Th2 responses (Everts et al., 2009). Although the
target receptor is currently unknown it has been suggested that
its ribonuclease activity is involved in this effect. Furthermore,
a number of studies have documented the potent effects of
cystatins, a class of molecules expressed by filiarial nematodes,
on host immune responses. Helminth cystatins from A. vitae,
B. Malayi, N. braisliensis, and O. volvolus interfere with DC anti-
gen presentation by blocking host cysteine protease activity (Klotz
et al., 2011). Bm-CPI-2, a cystatin from B. Malay was described
as interfering with antigen processing, which led to a reduced
number of epitopes presented to T cells in vitro (Manoury et al.,
2001). Recombinant AvCystatin, a cystatin derived fromA. vitae is
recognized bymacrophages and upon uptake induces phosphory-
lation of the mitogen-activated protein kinase signaling pathway
ERK1/2 and p38 in macrophages, leading to induce IL-10 secre-
tion (Hartmann et al., 1997). Finally, helminth pathogens express
cysteine proteases, termed cathepsines, which cause immune
deviation by suppressing Th1 immunity. Based on observations of
Der p1, one of the major allergens in house dust, it is conceivable
for helminth-derived proteases to have the potential to favor Th2
polarization through functional modulation of DC (Hammad
et al., 200
tion of TRIF-dependent signaling via degradation of TLR3 within
the endosome (Donelly et al., 2010).
HELMINTH-DERIVED IMMUNOMODULATORY
MOLECULES
Whilst the exact signaling pathways by which immune responses
are initiated remains obscure, helminth products seem able to
interact with host cells and interfere with their function via
distinct mechanisms including Treg, B cells and induction of reg-
ulatory cytokines such as IL-10 and TGF-β as discussed in the
previous sections.
Several studies led to the discovery of specific immunomod-
ulatory helminth-derived molecules and products inducing
microenvironments beneficial for parasites while at the same
time blocking autoimmune responses (Adisakwattana et al., 2009;
Danilowicz-Luebert et al., 2011). Many helminth molecules are
homologous to mammalian cytokines. For example two TGF-β
homologs found in Brugia species, Bm-tgh-1 and Bm-tgh-2 have
been well characterized (Gomez-Escobar et al., 2000). Similarly,
S. mansoni male worms express a member of the TGF-β receptor
family known as SmRK-1 (Beall and Pearce, 2001), and a product
secreted by H. polygyrus contains remarkable TGF-β-like activity
inducing Foxp3 expression in naïve T cells, modulating immune
function (Grainger et al., 2010).
Another well characterized helminth molecule is ES-62, a
glycoprotein from the rodent nematode A. vitae which exerts sev-
eral immunomodulatory effects including inhibition of B- and
T-lymphocyte proliferation, inhibition of IFN-γ, IL-12, and IL-17
secretion, and inhibition of maturation of naive DCs priming
T cells (Harnett and Harnett, 2009). These effects seem to be
dependent on phosphorylcholine moieties present on glycopro-
teins secreted by the parasites. These immunological effects have
been observed during therapeutic administration of ES-62 after
collagen-induced arthritis induction in mice, resulting in signifi-
cant reduction of disease severity and progression (Adisakwattana
et al., 2009; Mastisz et al., 2011). Likewise, when rDiAg, a prod-
uct from the filarial parasite Dirofilaria immitis, is administered
to NODmice it completely prevents insulinitis and diabetes onset
(Imai et al., 2001). Furthermore, S. mansoni-specific lysophos-
phatidylserine activates TLR2 at the cell surface of DCs, gener-
ating mature DCs with the ability to promote IL-10 secreting
regulatory T cell development. Similarly, other products derived
from S. mansoni modulate the immune response. Sm16 activates
the production of IL-1 receptor antagonists from human ker-
atinocytes, inducing secretion IL-10 and down-regulating ICAM-
1 expression. Lacto-N-fucopentose III (LNFP III) contained in
Schistosoma eggs is an oligosaccharide that induces IL-10 pro-
ducing B1 cells in mice (Velupillai et al., 1997). SmCKBP secreted
from S. mansoni, S. haematobium, and S. japonicum eggs, sup-
presses inflammation by binding to different chemokine subfam-
ilies (Adisakwattana et al., 2009). Finally, products from Ascaris
suum have also been described to contain immunomodulatory
properties. The administration of PAS-1 a 200 kDa protein from
A. suum to mice that have been injected with LPS results in
significant decrease in neutrophil migration, increase in IL-10
production, as well as suppression of IL-6, TNF-α, and IL-1β
(Oshiro et al., 2005).
CONCLUDING REMARKS
Parasites inhabit immune-competent hosts for long periods and
can therefore develop modulatory molecules, generating strong
anti-inflammatory responses that on one hand may restrict host
tissue damage, but on the other can also enhance parasite sur-
vival. Several studies have demonstrated that chronic helminth
infections in particular, but not acute infections, are associated
with the expression of regulatory networks necessary for down
modulating autoimmune responses to harmless antigens. In addi-
tion, worm glycans may play a role in helminth-induced biasing
of the immune response, contributing to the observed protec-
tion against autoimmune diseases. Significant interest has arisen
in defining and characterizing specific helminth molecules with
important immunomodulatory capacities as targets for thera-
peutic applications in the treatment or prophylaxis of autoim-
mune diseases. It would be dangerous, however, to ignore the
fact that this regulatory environment may hamper essential
and necessary responses to other antigens, vaccinations, and
life-threatening pathogens. The concern exists because wherever
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helminth infections are prevalent, so too are dangerous microbial
agents such as Mycobacterium tuberculosis, human immunode-
ficiency virus, and malarial parasites. Impaired Th1 responses
to tetanus toxoid immunization (van Riet et al., 2008) and
against influenza virus in Schistosoma and Onchocerca infected
patients (van Riet et al., 2007, 2008) have also been reported,
as well as reduced responses to BCG vaccination and to the
cholera vaccine during intestinal helminth infection (Elias et al.,
2008). Another area of specific safety concern is the possibil-
ity of helminths becoming pathogenic in patients with impaired
immunity like those treated with immune suppressive medica-
tions. For example, S. Stercolaris could multiply and the infection
become fulminant when hosts are treated with glucocorticoids
(Elliot and Weinstock, 2009). Improving current knowledge of
these effects is therefore essential for the development of novel
therapeutic approaches for the treatment of autoimmune diseases
such as MS. It would be critical to focus on the investigation
of immunomodulatory helminth-derived molecules to selectively
induce regulatory immune responses, and avoid any possible side
effects of natural worm infections. Serious efforts should also be
made to generate antigen-specific immunoregulation in order to
circumvent possible interference with essential responses to other
antigens.
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